M100700053 shivani kakria
52
SHIVANI KAKRIA
-
Upload
shivanikakria -
Category
Documents
-
view
922 -
download
0
Transcript of M100700053 shivani kakria
SHIVANI KAKRIA
CARING AND CURING
INNOVATION IS THE ESSENCE MISSION OF NOVARTIS.
HEALTHCARE THAT FOCUSES ON CREATING,DEVELOPING AND MANUFACTURING A WIDE RANGEOFCOMPETITIVELY DIFFERENTIATED PRODUCTSTHAT RESTORE,MAINTAIN AND IMPROVE THE HEALTH AND WELL-BEING OF CUSTOMERS.
CHAIRMAN : DANIEL VASELLA
CEO: JOSEPH JIMENEZ
GROWTH IN VARIOUS PRODUCT CATEGORIES…..
oCHINA
oRUSSIA
oTURKEY
oSOUTH KOREA
oBRAZIL
oINDIA
WE OFFER A BROAD RANGE OF HEALTHCARE SOLUTIONS THAT MEETSTHE EVOLVING AND UNMET NEEDS OF PATIENTS AND SOCITIESWORLDWIDE.
OUR MEDICINES AND VACCINES PROTECTED 930 MILLIONPEOPLE IN 2009.
STRONG FINANCIAL PERFORMANCE SHOWS OUR ABILITY TOTO FULFILL OUR PRIMARY MISSIONTO CARE AND CURE..
WHERE INTEGERITY AND HIGH ETHICAL STANDARDS REMAINSESSENTIAL TO OUR LONG TERM SUCCESS.
IssuerAmount(in millions)
Coupon Maturity
Novartis Capital Corp. 2,000 1.900% 2013
Novartis Capital Corp. 2,000 4.125% 2014
Novartis Capital Corp. 2,000 2.900% 2015
Novartis SecuritiesInvestment Ltd.
3,000 5.125% 2019
Novartis Capital Corp. 1,000 4.400% 2020
NET SALES:RISE 7%(+11% IN LOCAL CURRENCY TO USD 44.3BILLION.
PHARMACEUTICALS: RANKS AS ONE OF THE INDUSTRY FAST GROWING COMPANIES IN 2009 WITH NET SALES OF 8%(+12% IN LC) TO USD 28.5BILLION.
VACCINES AND DIAGNOSTICS:38%(39% IN LC) NET SALES INCCREASE TO USD 2.4 BILLION..
SANDOZ: NET SALES FALLS 1% TO USD 7.5 BILLION BUT RISE 5%LC AS NEGATIVE CURRENCY OVERSHADOWS OPERATIONAL GAINS FROM NEW LAUNCHES.
CONSUMER HEALTH:EXPAND MARKET SHARE IN ALL BUSINESS ECONOMIC ACTIVITIES WITH SALES OF USD 5.8 BILLION.
OPERATING INCOME:ADVANCES 11% TO USD 10.0 BILLION ON THE SOLID BUSINESS EXPANSIONAND PRODUCTIVITY GAINS MORE DUE TO NEGATIVE IMPACT OF LOCAL CURRENCY.
NET INCOME:GROWS 4% TO USD 8.5 BILLION DUE TO RELATED FINANCIAL COST AND INCOME FROM ASSOCIATED COMPANIES.
BASIC EARNING PER SHARE:RISE FROM 3% TO 3.70,CORE EPS RISES FROM 8% TO USD 4.50.
DIVIDEND:INCREASES 3.7%
PRODUCTIVITY:EXCEEDING THE TARGET BY 0.7 BILLION.
PHARMACEUTICAL
VACCINES AND DIAGNOSTICS
SANDOZ(GENERICS)
OVER THE COUNTER
ANIMAL HEALTH
CIBA VISION
Comtan- $420 M (2007)- Parkinson's disease
Diovan- $5.0 B sales[25] (2007)- Hypertension
Exjade- $357 M (2007) - Iron chelator
Femara- $937 M (2007)- Breast cancer
Gleevec- $3.1 B- for Chronic myeloid leukemia
Lescol- $665 M (2007)- hypercholesterolemia
Lotrel- $748 M (2007)- Hypertension
Lucentis- $393 M (2007)- Age-related macular degeneration
Ritalin- $375 M (2007) - AD/HD
Exelon- $632 M (2007)- Alzheimer's disease
Sandimmune and Neoral- $944 M (2007)- Organ transplantation
Sandostatin - $1.0 B (2007) - Acromegaly
Tegretol- $413 M (2007)- Epilepsy
Termalgin - (Paracetamol and compounds.) - Treatment of fever and light pain.
Tobramycin- $273 M (2007)- Cystic fibrosis
Trileptal- $692 M (2007)- Epilepsy
Voltaren- $747 M (2007)- anti-inflammatory
Zometa- $1.3 B (2007)- Cancer complications
Tofranil- - antidepressant
BenefiberBuckley's cold and cough formulaBufferinComtrex cold and coughDenavir/VectavirDesenexDoan's pain reliefEx-LaxExcedrinFenistilGas-XHabitrolKeri skin careLamisil foot careLipactin Herpes symptomatic treatmentMaaloxNicotinellNo-doz
PETS CARE
Interceptor (Milbemycin oxime), oral worm control productSentinel Flavor Tabs (Milbemycin oxime, Lufenuron), oral flea control productDeramaxx (Deracoxib), oral treatment for pain and inflammation from osteoarthritis in dogsCaps tar (Nitenpyram), oral tablet for flea controlMilbemax (Milbemycin oxime, Praziquantel), oral worm treatmentProgram (Lufenuron), oral tablet for flea control
LIVESTOCK
Acatalk Duostar (Fluazuron, Ivermectin), tick control for cattleCLiK (Dicyclanil), blowfly control for sheepDenagard (Tiamulin)Fasinex (Triclabendazole)ViraShield
0
20
40
60
PHARMACEUTICAL
VACCINES AND
DIAGNOSTICS
SANDOZ
0
20
40
60
80
PHARMACEUTICAL
VACCINES AND
DIAGNOSTICS
SANDOZ
PHARMACEUTICALSANDOZ
0
20
40
60
80 PHARMACEUTICAL
VACCINES AND
DIAGNOSTICS
SANDOZ
CONSUMER
HEALTH
NAME OF THE COUNTRY
1. DR.REDDY’S LAB2. CIPLA3. PIRAMAL
HEALTHCARE4. GLAXO INDIA LTD.5. SUN
PHARMACEUTICAL
TOTAL REVENUE
(IN USD BILLIONS)
1.5
1.28
0.84
0.43
0.42
NAME OF THE COUNTRY
1. HOFFMAN LA ROCHE
2.NYCOMED
TOTAL REVENUE
(IN USD BILLIONS)
47.35
4.26
NAME OF THE COUNTRY
1. BAYER
2. BOEHRINGER INGELHEIM
3. MERCK kGaA
TOTAL REVENUE
(IN USD BILLIONS)
22.3
16.9
5.17
NAME OF THE COUNTRY
1. TAKEDAPHARMACEUTICAL.
2. ASTELLAS PHARMA
3. DAIICHI SANKYO 9
4. EISAI
5. CHUGAI PHARMACEUTICAL .
TOTAL REVENUE(IN USD BILLIONS)
15.6
10.7
9
5.5
2.0
NAME OF THE COMPANY
1. JOHNSON AND JOHNSON
2. ABOTT LABORATORIES
3. MERC K AND CO.
4. ELI LILLY
5. BRISTOL MAYER SQUIBB
TOTAL REVENUE(IN USD BILLIONS )
61.90
30.76
27.43
21.84
18.81
NAMEOF THE COMPANY
TOTAL REVENUE
(IN USD BILLIONS)
45.83
32.811. GlaxoSmithKline
2. AstraZeneca
FORMULA:C24H29N5O3
MOL.MAS:435.519G/MOL
SMILES:eMolecules AND Pubchem
Bioavailability:25%
Protein binding:95%
Half life :6hours
Excretion:renal 30%,biliary70%
In patients with impaired glucose tolerance, valsartan may decrease the incidence of developing type 2 diabetes mellitus. However, the absolute risk reduction is small (<1%/year) and diet + exercise or
other drugs, maybe more protective. In the same study, no reduction in the rate of cardiovascular events (including death) was shown. In other words, taking Valsartan didn't make the patients live longer.
IN US , VALSARTAN IS MARKETED UNDER TRADE MARK DIOVAN.
IN PAKISTAN ,IT IS MARKETED UNDER TRADE MARK ANGIOTAN.
IN INDIA,IT IS MARKETED BY CIPLA UNDER TRADE MARK VALTAN AND BY TORRENT PHARMACEUTICALS UNDER NAME
VALZAAR.
LEADS TO HEADACHE AND DIZZINESS.SENSTIVITY TO SUNLIGHT AND BRIGHT
ARTIFICIAL LIGHT.
THERE IS A CASE OF A STILLBIRTH IN WHICH VALSARTAN ISIMPLICATED.
THANKS
